Investigation of DEXA-C Anterior Cervical Interbody System (DEXA-C)
A Prospective, Multi-Center Investigation of the DEXA- C Anterior Cervical Interbody System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah Martineck, PA
- Phone Number: 716-870-7535
- Email: smartineck@auroraspine.us
Study Contact Backup
- Name: Matthew Goldstone
- Phone Number: 626-664-3364
- Email: mgoldstone@auroraspine.us
Study Locations
-
-
California
-
Orange, California, United States, 92868
- UCI Center for Clinical Research
-
-
Kentucky
-
Paducah, Kentucky, United States, 42003
- Orthopaedic Institute of Western KY
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Koga Neurosurgery
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73159
- Optima Orthopedics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must already be scheduled or planned for anterior cervical discectomy and fusion using the Dexa-C Anterior Interbody System C3-7 with supplemental fixation and/or allogenic bone graft composed of cancellous, cortical, and/or cortico-cancellous bone meeting on-label criteria.
- Radicular signs and symptoms in one or both arms (i.e., pain, paresthesia or paresis in a specific nerve root distribution).
- Diagnosis of cervical radiculopathy at one or two contiguous levels from C3-7 requiring open anterior cervical fusion and discectomy.
- Diagnosis of degenerative disc disease by radiographic evidence of cervical disc herniation and/or osteophytes accompanying clinical symptoms.
- At least 6 weeks prior conservative treatment (i.e. physical therapy, pain medication).
Exclusion Criteria:
- History of cervical spine surgery less than 12 months prior to surgery.
- Diagnosis of severe spondylosis.
- Patients requiring posterior cervical surgery, anterior cervical corpectomy, or revision surgery.
- Any member of a vulnerable population (ie. minors, adults who lack the ability to consent, pregnant women, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Single Arm Observational
Cervical Interbody Cage
|
The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery.
The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s).
Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fusion Assesment
Time Frame: 12 months
|
The primary outcomes of interest for this study will be fusion assessment at 3 months, 6 months and 12 months post-surgery. Fusion assessment from Static and Dynamic X-Ray (AP/LAT/Flex/Ex) using the following criteria: Bridging bone inside or outside of graft No lucencies at the graft-vertebral body junction Motion < 1mm |
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subsidence
Time Frame: 12 months
|
Secondary outcome measures will include subsidence.
Patient reported outcomes (Neck Disability Index on a 0-50 scale (NDI) and Visual Analog Scale for Pain (VAS) on a 0-10 scale will be collected at follow up visits and assessed compared to baseline.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 01-AUR-DEXA-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.